Protalix’s Strong Financial Performance and Promising Product Outlook Justify Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Protalix (PLX – Research Report). The associated price target remains the same with $15.00.

Ram Selvaraju has given his Buy rating due to a combination of factors including Protalix’s strong financial performance and promising product outlook. The company’s revenue for 2024 showed a significant increase, primarily driven by sales to Chiesi Farmaceutici and other partners. This growth is attributed to the commercialization of their key asset, Elfabrio, which is approved in multiple territories for the treatment of Fabry disease. Elfabrio’s design for a longer half-life and reduced dosing frequency, along with its competitive pricing, positions it well in the market.
Additionally, Protalix’s financial structure is robust, having cleared its long-term debt and ending 2024 with a healthy cash reserve. The recent regulatory validation in Europe for a less frequent dosing regimen further enhances Elfabrio’s market potential. The company’s strategic moves and the anticipated growth in the Fabry disease market, with potential royalties from Elfabrio, support the optimistic outlook and justify the Buy rating.